+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cell Therapy Biomanufacturing Market by Manufacturing Model (Allogeneic, Autologous), Therapy Area (Autoimmune, Cardiovascular, Neurological), End User, Process Stage, Cell Type - Global Forecast 2025-2030- Product Image
Cell Therapy Biomanufacturing Market by Manufacturing Model (Allogeneic, Autologous), Therapy Area (Autoimmune, Cardiovascular, Neurological), End User, Process Stage, Cell Type - Global Forecast 2025-2030- Product Image
New

Cell Therapy Biomanufacturing Market by Manufacturing Model (Allogeneic, Autologous), Therapy Area (Autoimmune, Cardiovascular, Neurological), End User, Process Stage, Cell Type - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 190 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6123307
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The cell therapy biomanufacturing landscape is at a pivotal juncture, driven by technological breakthroughs and evolving clinical demands. Over the past decade, advances in genetic engineering, automation, and closed processing systems have converged to transform once-theoretical treatments into viable therapeutic options. As the field matures, manufacturers face the imperative to scale complex workflows while ensuring reproducibility, regulatory compliance, and cost efficiency.

This executive summary introduces the critical factors shaping the industry today, from supply chain intricacies to emerging process innovations. By highlighting current challenges and potential pathways to sustainable scale-up, the narrative sets the stage for a deeper exploration of market dynamics, segment-specific insights, and actionable strategies. In doing so, it equips decision-makers with the context required to navigate an increasingly competitive and rapidly evolving sector.

Unprecedented Technological and Operational Shifts Reshaping the Cell Therapy Biomanufacturing Landscape with Holistic Process Integration

Technological integration and process optimization are redefining how cell therapies move from discovery to patient administration. Novel gene editing tools, including CRISPR-based systems, have enabled precise modifications, leading to enhanced safety profiles and improved therapeutic efficacy. Meanwhile, closed system automation has streamlined critical tasks such as cell isolation and culture expansion, reducing contamination risk and manual variability.

Regulatory bodies worldwide are responding by harmonizing guidelines to facilitate global clinical trial alignment and market access. This confluence of innovation and regulatory convergence is fostering greater collaboration among industry stakeholders, contract developers, and academic research institutes. Consequently, end-to-end digital platforms are emerging to unify data management, quality control, and traceability across decentralized processing sites, ultimately accelerating the translation of laboratory-scale discoveries into standardized, off-the-shelf therapies.

Assessing the Far Reaching Consequences of New United States Tariff Measures on Global Cell Therapy Biomanufacturing Supply Chains and Costs

Recent announcements regarding revised United States tariff structures, set to take effect in 2025, are exerting significant influence on global sourcing strategies for raw materials and critical reagents. As import duties rise on specialized cell culture media, reagents, and bioreactor components, manufacturers are compelled to reassess supplier relationships and supply chain resilience. Procurement teams are evaluating dual sourcing and regional partnerships to mitigate cost volatility and ensure uninterrupted production.

In response, several organizations are forging strategic alliances with domestic suppliers, while others are exploring localized manufacturing hubs to bypass escalating duties. Additionally, technology providers are intensifying efforts to refine reagent formulations and streamline consumable usage, aiming to offset elevated input costs. These cumulative shifts underscore the necessity for agile supply chain frameworks and robust risk management practices to sustain growth under evolving trade policies.

Dissecting Core Segments of Cell Therapy Biomanufacturing to Illustrate Diverse Manufacturing Models and Specialty Process Pathways

A nuanced understanding of market segments illuminates distinct operational and strategic imperatives for industry participants. In terms of manufacturing models, allogeneic therapies hinge on off the shelf solutions or universal donor platforms that promise scale and broad patient coverage, while autologous approaches demand decentralized processing with patient specific workflows to ensure individualized product integrity.

Therapy area segmentation reveals divergent process requirements, as autoimmune applications often prioritize immune modulation, cardiovascular products focus on tissue regeneration, and neurological interventions necessitate stringent sterility standards to address central nervous system sensitivities. Oncology cell therapies bifurcate into hematologic malignancies, where rapid expansion and robust potency are paramount, and solid tumor treatments that require sophisticated tumor microenvironment targeting.

Considering end user environments, academic research institutes champion early stage innovation and process refinement, contract development and manufacturing organizations emphasize scalable and standardized service offerings, hospitals integrate in house processing labs for immediate patient needs, and pharmaceutical biotechnology companies align production strategies with global commercialization pathways-often establishing hospital based processing labs alongside specialty treatment centers to support site specific delivery.

Process stage segmentation highlights critical junctures that dictate overall workflow efficiency. Cryopreservation advancements in freeze thaw optimization and long term storage protocols preserve cell viability, while downstream processing through formulation and harvesting purification ensures product purity and stability. Upstream stages, encompassing cell culture expansion and separation, set the foundation for yield consistency and product potency.

Diversity in cell type further shapes manufacturing complexity. Dendritic cells require precise antigen loading protocols, hematopoietic stem cells demand optimized graft viability, induced pluripotent stem cells involve rigorous reprogramming controls, and mesenchymal stem cells sourced from adipose derived, bone marrow derived, or umbilical cord derived origins each entail unique expansion parameters. Meanwhile, natural killer cell therapies emphasize robust cytotoxic activation, and T cell applications span CAR T and TCR T modalities, each necessitating tailored transduction and activation processes.

Unearthing Regional Dynamics in Cell Therapy Biomanufacturing Across the Americas Europe Middle East Africa and Asia Pacific Arenas

Regional dynamics play a pivotal role in shaping competitive and collaborative landscapes across the cell therapy biomanufacturing domain. In the Americas, a robust ecosystem of academic institutions, contract developers, and biopharma players fosters innovation hubs in key metropolitan areas. Regulatory authorities in this region are increasingly supportive of accelerated approval pathways, propelling the translation of novel therapies into clinical trials.

Across Europe, the Middle East, and Africa, harmonized regulatory frameworks and pan regional initiatives are enhancing cross border collaborations. Leading contract manufacturers are establishing centers of excellence in Western Europe, while emerging markets are leveraging public private partnerships to bolster infrastructure and workforce capability. In parallel, region specific initiatives promote cost effective access to advanced therapies, stimulating local innovation and patient outreach.

The Asia Pacific region exhibits rapid capacity expansion driven by government investments and favorable reimbursement policies. Manufacturing clusters in key markets are prioritizing partnerships with technology vendors to modernize facilities and adopt Industry 4.0 practices. Furthermore, a growing number of regional centers are focused on developing indigenous cell therapy platforms, demonstrating the region’s ambition to transition from outsourced production to self sustaining innovation ecosystems.

Profiling Leading Innovators and Strategic Collaborators Pioneering Breakthroughs in Cell Therapy Biomanufacturing Excellence

A cohort of industry leaders is shaping the strategic direction of cell therapy biomanufacturing through targeted investments and innovative collaborations. Leading contract development and manufacturing organizations are expanding capacity with dedicated facilities optimized for aseptic processing and closed system automation. Simultaneously, biotechnology firms are forming alliances to integrate supply chain management with digital quality systems, enabling real time monitoring and compliance assurance.

Academic spin out companies are advancing next generation vectors and novel cell engineering platforms, while pharmaceutical corporations are conducting joint ventures to co develop allogeneic therapies with universal donor profiles. Process technology providers are responding by launching modular equipment that streamlines media preparation and cell enrichment workflows. This symbiotic network of partnerships underscores a shift towards integrated service models that combine research expertise, manufacturing scale, and regulatory acumen.

Formulating Strategic Recommendations to Propel Stakeholders Towards Scalable Efficient and Compliant Cell Therapy Manufacturing Operations

Industry stakeholders should prioritize the adoption of integrated digital platforms that unify process analytics, quality control, and traceability across decentralized and centralized manufacturing sites. By implementing end to end digital twins and machine learning driven predictive maintenance, organizations can reduce downtime and enhance reproducibility. Concurrently, forging strategic partnerships with regional suppliers will mitigate supply chain risks associated with shifting trade policies and tariff landscapes.

Investing in workforce training programs that focus on specialized skill sets for aseptic processing, quality assurance, and regulatory compliance will build organizational resilience. Furthermore, active engagement with regulatory agencies to co create guidance documents and leverage accelerated approval pathways will streamline product development. Finally, benchmarking against industry leaders and participating in consortiums will facilitate knowledge exchange and expedite adoption of best practices throughout the value chain.

Employing Rigorous Research Methodologies to Deliver an Accurate Holistic Analysis of the Cell Therapy Biomanufacturing Ecosystem

The insights presented in this report are derived from a rigorous multi phase research approach combining both qualitative and quantitative methodologies. Secondary research included a comprehensive review of peer reviewed journals, regulatory filings, patent landscapes, and corporate disclosures to map technology trends and strategic initiatives. Simultaneously, primary research comprised in depth interviews with senior executives, process engineers, and regulatory experts to validate findings and capture forward looking perspectives.

Data triangulation was applied to reconcile information from disparate sources, ensuring analytical robustness. A cross functional validation committee conducted iterative reviews of key assumptions and narrative frameworks. Furthermore, case study analyses of representative manufacturing sites provided real world context to process optimization and capacity planning discussions. Together, these research methodologies deliver an accurate, impartial, and holistic analysis of the cell therapy biomanufacturing ecosystem.

Concluding Insights Highlighting The Imperative Steps And Collaborative Efforts Driving Sustainable Growth In The Cell Therapy Manufacturing Sector

The imperative for innovation and collaboration in cell therapy biomanufacturing has never been greater. This summary has identified transformative process technologies, evolving supply chain dynamics, and regulatory shifts as critical factors shaping the industry’s trajectory. Segment specific insights underscore the diversity of operational requirements across manufacturing models, therapeutic areas, and cell types.

Regional analysis highlights the importance of localized partnerships and infrastructure investments, while company profiling reveals the strategic interplay between technology providers, contract developers, and biopharma innovators. By synthesizing these findings, it becomes clear that organizations adopting integrated digital solutions, agile supply chains, and proactive regulatory engagement will be best positioned to achieve sustainable growth and maintain competitive advantage in this dynamic field.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Manufacturing Model
    • Allogeneic
      • Off The Shelf
      • Universal Donor Platform
    • Autologous
      • Decentralized Processing
      • Patient Specific Workflow
  • Therapy Area
    • Autoimmune
    • Cardiovascular
    • Neurological
    • Oncology
      • Hematologic Malignancies
      • Solid Tumors
    • Orthopedic
  • End User
    • Academic Research Institute
    • Contract Development And Manufacturing Organization
    • Hospital
      • Hospital Based Processing Lab
      • Specialty Treatment Centers
    • Pharmaceutical Biotechnology Company
  • Process Stage
    • Cryopreservation
      • Freeze Thaw Optimization
      • Storage
    • Downstream Processing
      • Formulation
      • Harvesting Purification
    • Fill Finish
    • Upstream Processing
      • Cell Culture Expansion
      • Cell Separation
  • Cell Type
    • Dendritic Cell Therapy
    • Hematopoietic Stem Cell
    • Induced Pluripotent Stem Cell
    • Mesenchymal Stem Cell
      • Adipose Derived
      • Bone Marrow Derived
      • Umbilical Cord Derived
    • Natural Killer Cell Therapy
    • T Cell Therapy
      • CAR T
      • TCR T
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • Lonza Group AG
  • Thermo Fisher Scientific Inc.
  • Catalent, Inc.
  • WuXi AppTec Co., Ltd.
  • Sartorius AG
  • Miltenyi Biotec GmbH
  • AGC Biologics, Inc.
  • FUJIFILM Irvine Scientific, Inc.
  • Danaher Corporation
  • Charles River Laboratories International, Inc.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Adoption of automation and robotics in autologous cell therapy manufacturing lines to boost throughput and consistency
5.2. Implementation of closed system bioreactors with inline process analytics for scalable allogeneic cell therapies
5.3. Integration of artificial intelligence and machine learning for real-time process analytics and predictive quality control in cell therapy production
5.4. Emergence of decentralized point-of-care manufacturing models for personalized CAR T therapies in regional hospital networks
5.5. Development of standardized single use modular production units to reduce cross contamination risks and facility footprint
5.6. Advancements in supply chain digitization and real-time traceability solutions for cell collection processing and cryopreservation
5.7. Regulatory alignment initiatives between FDA EMA and PMDA to harmonize CGMP requirements for global cell therapy commercialization
5.8. Growing partnerships between contract manufacturing organizations and biotech innovators to accelerate process development and tech transfer timelines
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Cell Therapy Biomanufacturing Market, by Manufacturing Model
8.1. Introduction
8.2. Allogeneic
8.2.1. Off the Shelf
8.2.2. Universal Donor Platform
8.3. Autologous
8.3.1. Decentralized Processing
8.3.2. Patient Specific Workflow
9. Cell Therapy Biomanufacturing Market, by Therapy Area
9.1. Introduction
9.2. Autoimmune
9.3. Cardiovascular
9.4. Neurological
9.5. Oncology
9.5.1. Hematologic Malignancies
9.5.2. Solid Tumors
9.6. Orthopedic
10. Cell Therapy Biomanufacturing Market, by End User
10.1. Introduction
10.2. Academic Research Institute
10.3. Contract Development and Manufacturing Organization
10.4. Hospital
10.4.1. Hospital Based Processing Lab
10.4.2. Specialty Treatment Centers
10.5. Pharmaceutical Biotechnology Company
11. Cell Therapy Biomanufacturing Market, by Process Stage
11.1. Introduction
11.2. Cryopreservation
11.2.1. Freeze Thaw Optimization
11.2.2. Storage
11.3. Downstream Processing
11.3.1. Formulation
11.3.2. Harvesting Purification
11.4. Fill Finish
11.5. Upstream Processing
11.5.1. Cell Culture Expansion
11.5.2. Cell Separation
12. Cell Therapy Biomanufacturing Market, by Cell Type
12.1. Introduction
12.2. Dendritic Cell Therapy
12.3. Hematopoietic Stem Cell
12.4. Induced Pluripotent Stem Cell
12.5. Mesenchymal Stem Cell
12.5.1. Adipose Derived
12.5.2. Bone Marrow Derived
12.5.3. Umbilical Cord Derived
12.6. Natural Killer Cell Therapy
12.7. T Cell Therapy
12.7.1. CAR T
12.7.2. TCR T
13. Americas Cell Therapy Biomanufacturing Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Cell Therapy Biomanufacturing Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Cell Therapy Biomanufacturing Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Lonza Group AG
16.3.2. Thermo Fisher Scientific Inc.
16.3.3. Catalent, Inc.
16.3.4. WuXi AppTec Co., Ltd.
16.3.5. Sartorius AG
16.3.6. Miltenyi Biotec GmbH
16.3.7. AGC Biologics, Inc.
16.3.8. FUJIFILM Irvine Scientific, Inc.
16.3.9. Danaher Corporation
16.3.10. Charles River Laboratories International, Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. CELL THERAPY BIOMANUFACTURING MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2024 VS 2030 (%)
FIGURE 6. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY THERAPY AREA, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY THERAPY AREA, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY PROCESS STAGE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY PROCESS STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CELL TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CELL TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. CELL THERAPY BIOMANUFACTURING MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. CELL THERAPY BIOMANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. CELL THERAPY BIOMANUFACTURING MARKET: RESEARCHAI
FIGURE 26. CELL THERAPY BIOMANUFACTURING MARKET: RESEARCHSTATISTICS
FIGURE 27. CELL THERAPY BIOMANUFACTURING MARKET: RESEARCHCONTACTS
FIGURE 28. CELL THERAPY BIOMANUFACTURING MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. CELL THERAPY BIOMANUFACTURING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ALLOGENEIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ALLOGENEIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY OFF THE SHELF, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY OFF THE SHELF, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY UNIVERSAL DONOR PLATFORM, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY UNIVERSAL DONOR PLATFORM, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ALLOGENEIC, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ALLOGENEIC, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY DECENTRALIZED PROCESSING, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY DECENTRALIZED PROCESSING, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY PATIENT SPECIFIC WORKFLOW, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY PATIENT SPECIFIC WORKFLOW, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY AUTOLOGOUS, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY AUTOLOGOUS, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY THERAPY AREA, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY AUTOIMMUNE, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY AUTOIMMUNE, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY NEUROLOGICAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY NEUROLOGICAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY SOLID TUMORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ORTHOPEDIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ORTHOPEDIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTE, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTE, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY HOSPITAL BASED PROCESSING LAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY HOSPITAL BASED PROCESSING LAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY SPECIALTY TREATMENT CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY SPECIALTY TREATMENT CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY PHARMACEUTICAL BIOTECHNOLOGY COMPANY, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY PHARMACEUTICAL BIOTECHNOLOGY COMPANY, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY PROCESS STAGE, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY PROCESS STAGE, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CRYOPRESERVATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CRYOPRESERVATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY FREEZE THAW OPTIMIZATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY FREEZE THAW OPTIMIZATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY STORAGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY STORAGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CRYOPRESERVATION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CRYOPRESERVATION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY FORMULATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY FORMULATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY HARVESTING PURIFICATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY HARVESTING PURIFICATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY FILL FINISH, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY FILL FINISH, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CELL CULTURE EXPANSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CELL CULTURE EXPANSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CELL SEPARATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CELL SEPARATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY DENDRITIC CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY DENDRITIC CELL THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY HEMATOPOIETIC STEM CELL, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY HEMATOPOIETIC STEM CELL, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELL, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELL, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MESENCHYMAL STEM CELL, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MESENCHYMAL STEM CELL, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ADIPOSE DERIVED, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ADIPOSE DERIVED, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY BONE MARROW DERIVED, BY REGION, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY BONE MARROW DERIVED, BY REGION, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY UMBILICAL CORD DERIVED, BY REGION, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY UMBILICAL CORD DERIVED, BY REGION, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MESENCHYMAL STEM CELL, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MESENCHYMAL STEM CELL, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY NATURAL KILLER CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY NATURAL KILLER CELL THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY T CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY T CELL THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 111. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CAR T, BY REGION, 2018-2024 (USD MILLION)
TABLE 112. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CAR T, BY REGION, 2025-2030 (USD MILLION)
TABLE 113. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY TCR T, BY REGION, 2018-2024 (USD MILLION)
TABLE 114. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY TCR T, BY REGION, 2025-2030 (USD MILLION)
TABLE 115. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY T CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 116. GLOBAL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY T CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 117. AMERICAS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2024 (USD MILLION)
TABLE 118. AMERICAS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2025-2030 (USD MILLION)
TABLE 119. AMERICAS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ALLOGENEIC, 2018-2024 (USD MILLION)
TABLE 120. AMERICAS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ALLOGENEIC, 2025-2030 (USD MILLION)
TABLE 121. AMERICAS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY AUTOLOGOUS, 2018-2024 (USD MILLION)
TABLE 122. AMERICAS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY AUTOLOGOUS, 2025-2030 (USD MILLION)
TABLE 123. AMERICAS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
TABLE 124. AMERICAS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY THERAPY AREA, 2025-2030 (USD MILLION)
TABLE 125. AMERICAS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 126. AMERICAS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 127. AMERICAS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 128. AMERICAS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 129. AMERICAS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 130. AMERICAS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 131. AMERICAS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY PROCESS STAGE, 2018-2024 (USD MILLION)
TABLE 132. AMERICAS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY PROCESS STAGE, 2025-2030 (USD MILLION)
TABLE 133. AMERICAS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CRYOPRESERVATION, 2018-2024 (USD MILLION)
TABLE 134. AMERICAS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CRYOPRESERVATION, 2025-2030 (USD MILLION)
TABLE 135. AMERICAS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2024 (USD MILLION)
TABLE 136. AMERICAS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2025-2030 (USD MILLION)
TABLE 137. AMERICAS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2024 (USD MILLION)
TABLE 138. AMERICAS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2025-2030 (USD MILLION)
TABLE 139. AMERICAS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
TABLE 140. AMERICAS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
TABLE 141. AMERICAS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MESENCHYMAL STEM CELL, 2018-2024 (USD MILLION)
TABLE 142. AMERICAS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MESENCHYMAL STEM CELL, 2025-2030 (USD MILLION)
TABLE 143. AMERICAS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY T CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 144. AMERICAS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY T CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 145. AMERICAS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 146. AMERICAS CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 147. UNITED STATES CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2024 (USD MILLION)
TABLE 148. UNITED STATES CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2025-2030 (USD MILLION)
TABLE 149. UNITED STATES CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ALLOGENEIC, 2018-2024 (USD MILLION)
TABLE 150. UNITED STATES CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ALLOGENEIC, 2025-2030 (USD MILLION)
TABLE 151. UNITED STATES CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY AUTOLOGOUS, 2018-2024 (USD MILLION)
TABLE 152. UNITED STATES CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY AUTOLOGOUS, 2025-2030 (USD MILLION)
TABLE 153. UNITED STATES CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
TABLE 154. UNITED STATES CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY THERAPY AREA, 2025-2030 (USD MILLION)
TABLE 155. UNITED STATES CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 156. UNITED STATES CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 157. UNITED STATES CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 158. UNITED STATES CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 159. UNITED STATES CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 160. UNITED STATES CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 161. UNITED STATES CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY PROCESS STAGE, 2018-2024 (USD MILLION)
TABLE 162. UNITED STATES CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY PROCESS STAGE, 2025-2030 (USD MILLION)
TABLE 163. UNITED STATES CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CRYOPRESERVATION, 2018-2024 (USD MILLION)
TABLE 164. UNITED STATES CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CRYOPRESERVATION, 2025-2030 (USD MILLION)
TABLE 165. UNITED STATES CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2024 (USD MILLION)
TABLE 166. UNITED STATES CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2025-2030 (USD MILLION)
TABLE 167. UNITED STATES CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2024 (USD MILLION)
TABLE 168. UNITED STATES CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2025-2030 (USD MILLION)
TABLE 169. UNITED STATES CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
TABLE 170. UNITED STATES CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
TABLE 171. UNITED STATES CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MESENCHYMAL STEM CELL, 2018-2024 (USD MILLION)
TABLE 172. UNITED STATES CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MESENCHYMAL STEM CELL, 2025-2030 (USD MILLION)
TABLE 173. UNITED STATES CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY T CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 174. UNITED STATES CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY T CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 175. UNITED STATES CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 176. UNITED STATES CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 177. CANADA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2024 (USD MILLION)
TABLE 178. CANADA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2025-2030 (USD MILLION)
TABLE 179. CANADA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ALLOGENEIC, 2018-2024 (USD MILLION)
TABLE 180. CANADA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ALLOGENEIC, 2025-2030 (USD MILLION)
TABLE 181. CANADA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY AUTOLOGOUS, 2018-2024 (USD MILLION)
TABLE 182. CANADA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY AUTOLOGOUS, 2025-2030 (USD MILLION)
TABLE 183. CANADA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
TABLE 184. CANADA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY THERAPY AREA, 2025-2030 (USD MILLION)
TABLE 185. CANADA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 186. CANADA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 187. CANADA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 188. CANADA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 189. CANADA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 190. CANADA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 191. CANADA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY PROCESS STAGE, 2018-2024 (USD MILLION)
TABLE 192. CANADA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY PROCESS STAGE, 2025-2030 (USD MILLION)
TABLE 193. CANADA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CRYOPRESERVATION, 2018-2024 (USD MILLION)
TABLE 194. CANADA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CRYOPRESERVATION, 2025-2030 (USD MILLION)
TABLE 195. CANADA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2024 (USD MILLION)
TABLE 196. CANADA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2025-2030 (USD MILLION)
TABLE 197. CANADA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2024 (USD MILLION)
TABLE 198. CANADA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2025-2030 (USD MILLION)
TABLE 199. CANADA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
TABLE 200. CANADA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
TABLE 201. CANADA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MESENCHYMAL STEM CELL, 2018-2024 (USD MILLION)
TABLE 202. CANADA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MESENCHYMAL STEM CELL, 2025-2030 (USD MILLION)
TABLE 203. CANADA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY T CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 204. CANADA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY T CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 205. MEXICO CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2024 (USD MILLION)
TABLE 206. MEXICO CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2025-2030 (USD MILLION)
TABLE 207. MEXICO CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ALLOGENEIC, 2018-2024 (USD MILLION)
TABLE 208. MEXICO CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ALLOGENEIC, 2025-2030 (USD MILLION)
TABLE 209. MEXICO CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY AUTOLOGOUS, 2018-2024 (USD MILLION)
TABLE 210. MEXICO CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY AUTOLOGOUS, 2025-2030 (USD MILLION)
TABLE 211. MEXICO CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
TABLE 212. MEXICO CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY THERAPY AREA, 2025-2030 (USD MILLION)
TABLE 213. MEXICO CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 214. MEXICO CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 215. MEXICO CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 216. MEXICO CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 217. MEXICO CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 218. MEXICO CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 219. MEXICO CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY PROCESS STAGE, 2018-2024 (USD MILLION)
TABLE 220. MEXICO CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY PROCESS STAGE, 2025-2030 (USD MILLION)
TABLE 221. MEXICO CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CRYOPRESERVATION, 2018-2024 (USD MILLION)
TABLE 222. MEXICO CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CRYOPRESERVATION, 2025-2030 (USD MILLION)
TABLE 223. MEXICO CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2024 (USD MILLION)
TABLE 224. MEXICO CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2025-2030 (USD MILLION)
TABLE 225. MEXICO CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2024 (USD MILLION)
TABLE 226. MEXICO CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2025-2030 (USD MILLION)
TABLE 227. MEXICO CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
TABLE 228. MEXICO CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
TABLE 229. MEXICO CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MESENCHYMAL STEM CELL, 2018-2024 (USD MILLION)
TABLE 230. MEXICO CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MESENCHYMAL STEM CELL, 2025-2030 (USD MILLION)
TABLE 231. MEXICO CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY T CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 232. MEXICO CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY T CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 233. BRAZIL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2024 (USD MILLION)
TABLE 234. BRAZIL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2025-2030 (USD MILLION)
TABLE 235. BRAZIL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ALLOGENEIC, 2018-2024 (USD MILLION)
TABLE 236. BRAZIL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ALLOGENEIC, 2025-2030 (USD MILLION)
TABLE 237. BRAZIL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY AUTOLOGOUS, 2018-2024 (USD MILLION)
TABLE 238. BRAZIL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY AUTOLOGOUS, 2025-2030 (USD MILLION)
TABLE 239. BRAZIL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
TABLE 240. BRAZIL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY THERAPY AREA, 2025-2030 (USD MILLION)
TABLE 241. BRAZIL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 242. BRAZIL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 243. BRAZIL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 244. BRAZIL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 245. BRAZIL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 246. BRAZIL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 247. BRAZIL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY PROCESS STAGE, 2018-2024 (USD MILLION)
TABLE 248. BRAZIL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY PROCESS STAGE, 2025-2030 (USD MILLION)
TABLE 249. BRAZIL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CRYOPRESERVATION, 2018-2024 (USD MILLION)
TABLE 250. BRAZIL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CRYOPRESERVATION, 2025-2030 (USD MILLION)
TABLE 251. BRAZIL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2024 (USD MILLION)
TABLE 252. BRAZIL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2025-2030 (USD MILLION)
TABLE 253. BRAZIL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2024 (USD MILLION)
TABLE 254. BRAZIL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2025-2030 (USD MILLION)
TABLE 255. BRAZIL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
TABLE 256. BRAZIL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
TABLE 257. BRAZIL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MESENCHYMAL STEM CELL, 2018-2024 (USD MILLION)
TABLE 258. BRAZIL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MESENCHYMAL STEM CELL, 2025-2030 (USD MILLION)
TABLE 259. BRAZIL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY T CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 260. BRAZIL CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY T CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 261. ARGENTINA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2024 (USD MILLION)
TABLE 262. ARGENTINA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2025-2030 (USD MILLION)
TABLE 263. ARGENTINA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ALLOGENEIC, 2018-2024 (USD MILLION)
TABLE 264. ARGENTINA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ALLOGENEIC, 2025-2030 (USD MILLION)
TABLE 265. ARGENTINA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY AUTOLOGOUS, 2018-2024 (USD MILLION)
TABLE 266. ARGENTINA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY AUTOLOGOUS, 2025-2030 (USD MILLION)
TABLE 267. ARGENTINA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
TABLE 268. ARGENTINA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY THERAPY AREA, 2025-2030 (USD MILLION)
TABLE 269. ARGENTINA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 270. ARGENTINA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 271. ARGENTINA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 272. ARGENTINA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 273. ARGENTINA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 274. ARGENTINA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 275. ARGENTINA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY PROCESS STAGE, 2018-2024 (USD MILLION)
TABLE 276. ARGENTINA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY PROCESS STAGE, 2025-2030 (USD MILLION)
TABLE 277. ARGENTINA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CRYOPRESERVATION, 2018-2024 (USD MILLION)
TABLE 278. ARGENTINA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CRYOPRESERVATION, 2025-2030 (USD MILLION)
TABLE 279. ARGENTINA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2018-2024 (USD MILLION)
TABLE 280. ARGENTINA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM PROCESSING, 2025-2030 (USD MILLION)
TABLE 281. ARGENTINA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2018-2024 (USD MILLION)
TABLE 282. ARGENTINA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY UPSTREAM PROCESSING, 2025-2030 (USD MILLION)
TABLE 283. ARGENTINA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
TABLE 284. ARGENTINA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
TABLE 285. ARGENTINA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MESENCHYMAL STEM CELL, 2018-2024 (USD MILLION)
TABLE 286. ARGENTINA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MESENCHYMAL STEM CELL, 2025-2030 (USD MILLION)
TABLE 287. ARGENTINA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY T CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 288. ARGENTINA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY T CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 289. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2024 (USD MILLION)
TABLE 290. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2025-2030 (USD MILLION)
TABLE 291. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ALLOGENEIC, 2018-2024 (USD MILLION)
TABLE 292. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ALLOGENEIC, 2025-2030 (USD MILLION)
TABLE 293. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY AUTOLOGOUS, 2018-2024 (USD MILLION)
TABLE 294. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY AUTOLOGOUS, 2025-2030 (USD MILLION)
TABLE 295. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2024 (USD MILLION)
TABLE 296. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY THERAPY AREA, 2025-2030 (USD MILLION)
TABLE 297. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 298. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 299. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 300. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 301. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY BIOMANUFACTURING MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 302.

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Cell Therapy Biomanufacturing market report include:
  • Lonza Group AG
  • Thermo Fisher Scientific Inc.
  • Catalent, Inc.
  • WuXi AppTec Co., Ltd.
  • Sartorius AG
  • Miltenyi Biotec GmbH
  • AGC Biologics, Inc.
  • FUJIFILM Irvine Scientific, Inc.
  • Danaher Corporation
  • Charles River Laboratories International, Inc.

Related Topics

Related Reports

Cell & Gene Therapy Biomanufacturing CDMO Market by Service Type (Analytical Services, Clinical Manufacturing, Commercial Manufacturing), Therapy Type (Cell Therapy, Gene Therapy), Technology, Application, Scale, End User, Process Stage - Global Forecast 2025-2030 - Product Image

Cell & Gene Therapy Biomanufacturing CDMO Market by Service Type (Analytical Services, Clinical Manufacturing, Commercial Manufacturing), Therapy Type (Cell Therapy, Gene Therapy), Technology, Application, Scale, End User, Process Stage - Global Forecast 2025-2030

  • Report
  • 186 Pages
  • Global
From
Digital Biomanufacturing Market by Product Type (Cell Therapy, Monoclonal Antibodies, Recombinant Proteins), Process Stage (Continuous Biomanufacturing, Downstream Processing, Upstream Processing), Technology, End User, Application - Global Forecast 2025-2030 - Product Image

Digital Biomanufacturing Market by Product Type (Cell Therapy, Monoclonal Antibodies, Recombinant Proteins), Process Stage (Continuous Biomanufacturing, Downstream Processing, Upstream Processing), Technology, End User, Application - Global Forecast 2025-2030

  • Report
  • 192 Pages
  • Global
From
Next-Generation Biomanufacturing Market by Product Type, Technology, Process Stage, End User, Operation Scale, Cell Line, Process Mode - Global Forecast 2025-2030 - Product Image

Next-Generation Biomanufacturing Market by Product Type, Technology, Process Stage, End User, Operation Scale, Cell Line, Process Mode - Global Forecast 2025-2030

  • Report
  • 193 Pages
  • Global
From
Cell and Gene Therapy Biomanufacturing Market - A Global and Regional Analysis: Focus on Product Type, Application, Usage, End User, and Region - Analysis and Forecast, 2025-2035 - Product Image

Cell and Gene Therapy Biomanufacturing Market - A Global and Regional Analysis: Focus on Product Type, Application, Usage, End User, and Region - Analysis and Forecast, 2025-2035

  • Report
  • 140 Pages
  • Global
From
Cell and Gene Therapy Biomanufacturing CDMO Market - Focused on AAV - A Global and Regional Analysis: Focus on Phase of Development, Workflow, Indication, Culture Type, and Region - Analysis and Forecast, 2023-2033 - Product Image

Cell and Gene Therapy Biomanufacturing CDMO Market - Focused on AAV - A Global and Regional Analysis: Focus on Phase of Development, Workflow, Indication, Culture Type, and Region - Analysis and Forecast, 2023-2033

  • Report
  • 336 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.